Creative Medical reports 93% response and ~65% pain reduction in knee osteoarthritis pilot
Creative Medical Technology Holdings presented results from a 30‑patient, open‑label, single‑arm pilot study of its Ultrasome cell‑free platform for bilateral knee osteoarthritis. Twenty‑eight participants met the study’s response criteria, showing about a 65% drop in average pain scores and a 52% decline in WOMAC scores over six months. Quality‑of‑life scores rose roughly 35 points, and no serious safety issues occurred during follow‑up. The company plans to submit a detailed manuscript for peer‑review publication.
Why it matters
The company’s press release says the data support further development of Ultrasome, which could expand its pipeline and attract additional funding. Investors should note that the results come from a small, uncontrolled study, so future trials will be needed to confirm efficacy.
Key facts
- 1The pilot study enrolled 30 patients with bilateral knee osteoarthritis and lasted six months. stocktitan.net
- 2Twenty‑eight of the 30 participants (93%) met the study‑defined response criteria. stocktitan.net
- 3Average pain scores fell by approximately 65% from baseline to six months. stocktitan.net
- 4Average WOMAC scores decreased by 52% over the same period. stocktitan.net
- 5The group’s knee‑related quality‑of‑life score increased by about 35 points. stocktitan.net
- 6No serious adverse events were observed during the six‑month follow‑up. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.